Spontaneous bacterial peritonitis secondary prevention: Difference between revisions
No edit summary |
|||
Line 7: | Line 7: | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
* All patients who have survived an episode of SBP should receive long-term prophylaxis with daily [[norfloxacin]] (or [[trimethoprim/sulfamethoxazole]]) because this is the most data-supported indication for long-term outpatient prophylaxis to prevent future episodes ( 40-70% risk of recurrence in 1 year ). <ref>http://guideline.gov/content.aspx?id=14887&search=ascitis</ref> | * All patients who have survived an episode of SBP should receive long-term prophylaxis with daily [[norfloxacin]] (or [[trimethoprim/sulfamethoxazole]]) because this is the most data-supported indication for long-term outpatient prophylaxis to prevent future episodes ( 40-70% risk of recurrence in 1 year ). <ref>http://guideline.gov/content.aspx?id=14887&search=ascitis</ref><ref name="GinésRimola1990">{{cite journal|last1=Ginés|first1=Pere|last2=Rimola|first2=Antoni|last3=Planas|first3=Ramón|last4=Vargas|first4=Victor|last5=Marco|first5=Francesc|last6=Almela|first6=Manuel|last7=Forne|first7=Montserrat|last8=Miranda|first8=Maria Luisa|last9=Llach|first9=Josep|last10=Salmerón|first10=Joan Manuel|last11=Esteve|first11=Maria|last12=Marques|first12=Josep Maria|last13=de Anta|first13=Maria Teresa Jiménez|last14=Arroyo|first14=Vicente|last15=Rodés|first15=Joan|title=Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: Results of a double-blind, placebo-controlled trial|journal=Hepatology|volume=12|issue=4|year=1990|pages=716–724|issn=02709139|doi=10.1002/hep.1840120416}}</ref> | ||
* All cirrhotic patients might benefit from antibiotics if: | * All cirrhotic patients might benefit from antibiotics if: |
Revision as of 18:30, 22 January 2017
Spontaneous bacterial peritonitis Microchapters |
Differentiating Spontaneous bacterial peritonitis from other Diseases |
Diagnosis |
Treatment |
Spontaneous bacterial peritonitis secondary prevention On the Web |
American Roentgen Ray Society Images of Spontaneous bacterial peritonitis secondary prevention |
FDA on Spontaneous bacterial peritonitis secondary prevention |
CDC on Spontaneous bacterial peritonitis secondary prevention |
Spontaneous bacterial peritonitis secondary prevention in the news |
Blogs on Spontaneous bacterial peritonitis secondary prevention |
Directions to Hospitals Treating Spontaneous bacterial peritonitis |
Risk calculators and risk factors for Spontaneous bacterial peritonitis secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2] Shivani Chaparala M.B.B.S [3]
Overview
Secondary Prevention
- All patients who have survived an episode of SBP should receive long-term prophylaxis with daily norfloxacin (or trimethoprim/sulfamethoxazole) because this is the most data-supported indication for long-term outpatient prophylaxis to prevent future episodes ( 40-70% risk of recurrence in 1 year ). [1][2]
- All cirrhotic patients might benefit from antibiotics if:
References
- ↑ http://guideline.gov/content.aspx?id=14887&search=ascitis
- ↑ Ginés, Pere; Rimola, Antoni; Planas, Ramón; Vargas, Victor; Marco, Francesc; Almela, Manuel; Forne, Montserrat; Miranda, Maria Luisa; Llach, Josep; Salmerón, Joan Manuel; Esteve, Maria; Marques, Josep Maria; de Anta, Maria Teresa Jiménez; Arroyo, Vicente; Rodés, Joan (1990). "Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: Results of a double-blind, placebo-controlled trial". Hepatology. 12 (4): 716–724. doi:10.1002/hep.1840120416. ISSN 0270-9139.
- ↑ Runyon BA (1986). "Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis". Gastroenterology. 91 (6): 1343–6. PMID 3770358.
- ↑ Grangé JD, Roulot D, Pelletier G; et al. (1998). "Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial". J. Hepatol. 29 (3): 430–6. PMID 9764990.